Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography

References

• Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384(9958):1953–1997.
   PubMed Web of Science ®Google Scholar
• Collaborators GMaCoD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Asrani SK, Larson JJ, Yawn B, et al. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375–382. e1–2.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1; quiz e60.
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Stram DO, Porcel J, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64(6):1969–1977.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Liver fibrosis – from bench to bedside. J. Hepatol. 2003;38 (Suppl 1):S38–S53.
   PubMed Web of Science ®Google Scholar
• Fleming KM, Aithal GP, Card TR, et al. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 2012;32(1):79–84.
   PubMed Web of Science ®Google Scholar
• Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–777.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–S50.
   PubMed Web of Science ®Google Scholar
• Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol. 2018;68(2):362–375.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344–353.
   PubMedGoogle Scholar
• Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996;25(5):649–654.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Nonalcoholic Steatohepatitis Clinical Research Network, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–1457.
   PubMed Web of Science ®Google Scholar
• Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41(2):257–264.
   PubMed Web of Science ®Google Scholar
• Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165–173.
   PubMed Web of Science ®Google Scholar
• Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–2618.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–1447.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854.
   PubMed Web of Science ®Google Scholar
• Lykiardopoulos B, Hagström H, Fredrikson M, et al. Development of serum marker models to increase diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease: the New LINKI algorithm compared with established algorithms. PLoS One. 2016;11(12):e0167776.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, APRICOT Clinical Investigators, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325.
   PubMed Web of Science ®Google Scholar
• Islam S, Antonsson L, Westin J, et al. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40(7):867–872.
   PubMed Web of Science ®Google Scholar
• Glaser KJ, Manduca A, Ehman RL. Review of MR elastography applications and recent developments. J Magn Reson Imaging. 2012;36(4):757–774.
   PubMed Web of Science ®Google Scholar
• Dyvorne HA, Jajamovich GH, Bane O, et al. Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. Liver Int. 2016;36(5):659–666.
   PubMed Web of Science ®Google Scholar
• Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–607.e2.
   PubMed Web of Science ®Google Scholar
• Noren B, Dahlqvist O, Lundberg P, et al. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. Eur J Radiol. 2008;66(2):313–320.
   PubMed Web of Science ®Google Scholar
• Lim AK, Patel N, Hamilton G, et al. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology. 2003;37(4):788–794.
   PubMed Web of Science ®Google Scholar
• Noren B, Forsgren MF, Dahlqvist Leinhard O, et al. Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. Eur Radiol. 2013;23(1):174–181.
   PubMed Web of Science ®Google Scholar
• Juluru K, Talal AH, Yantiss RK, et al. Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-EOB-DTPA-enhanced MRI for hepatic fibrosis stage. J Magn Reson Imaging. 2016;45: 1177–1185.
   PubMed Web of Science ®Google Scholar
• Forsgren MF, Dahlqvist Leinhard O, Dahlström N, et al. Physiologically realistic and validated mathematical liver model reveals [corrected] hepatobiliary transfer rates for Gd-EOB-DTPA using human DCE-MRI data. PLoS One. 2014;9(4):e95700.
   PubMed Web of Science ®Google Scholar
• Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J, et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol. 2012;22(3):642–653.
   PubMed Web of Science ®Google Scholar
• Nasr P, Forsgren MF, Ignatova S, et al. Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis. Gastroenterology. 2017;153(1):53–55.e7.
   PubMed Web of Science ®Google Scholar
• Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835–847.
   PubMed Web of Science ®Google Scholar
• Forsgren MF, Norén B, Kihlberg J, et al. Comparing hepatic 2D and 3D magnetic resonance elastography methods in a clinical setting – initial experiences. Eur J Radiol Open. 2015;2:66–70.
   PubMed Web of Science ®Google Scholar
• Forsgren MF, Karlsson M, Dahlqvist Leinhard O, et al. Model-inferred mechanisms of liver function from magnetic resonance imaging data: validation and variation across a clinically relevant cohort Model-inferred mechanisms of liver function from magnetic resonance imaging data: validation and variation across a clinically relevant cohort. PLoS Comput Biol. 2019;15(6):e1007157.
   PubMed Web of Science ®Google Scholar
• Norén B, Lundberg P, Ressner M, et al. Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease. Eur Radiol. 2005;15(1):148–157.
   PubMed Web of Science ®Google Scholar
• Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 2001;12(2–3):141–152.
   PubMedGoogle Scholar
• Vanhamme L,A, Vanhamme L, van den Boogaart A, et al. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129(1):35–43.
   PubMed Web of Science ®Google Scholar
• Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19(12):1409–1417.
   PubMed Web of Science ®Google Scholar
• Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135(1):32–40.
   PubMed Web of Science ®Google Scholar
• Godfrey EM, Patterson AJ, Priest AN, et al. A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. Eur Radiol. 2012;22(12):2790–2797.
   PubMed Web of Science ®Google Scholar
• Wang QB, Zhu H, Liu HL, et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology. 2012;56(1):239–247.
   PubMed Web of Science ®Google Scholar
• Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960–974.
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–1730.
   PubMed Web of Science ®Google Scholar
• Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–350.
   PubMed Web of Science ®Google Scholar
• Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology. 2006;43(5):1118–1124.
   PubMed Web of Science ®Google Scholar
• Godfrey EM, Mannelli L, Griffin N, et al. Magnetic resonance elastography in the diagnosis of hepatic fibrosis. Semin Ultrasound CT Mr. 2013;34(1):81–88.
   PubMed Web of Science ®Google Scholar
• Baranova A, Lal P, Birerdinc A, et al. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91.
   PubMed Web of Science ®Google Scholar
• Norén B, Dahlström N, Forsgren MF, et al. Visual assessment of biliary excretion of Gd-EOB-DTPA in patients with suspected diffuse liver disease – a biopsy-verified prospective study. Eur J Radiol Open. 2015;2:19–25.
   PubMed Web of Science ®Google Scholar
• Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782–789.e4.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Baretton GB, Oswald M, et al. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res. 2002;23(1):78–82.
   PubMed Web of Science ®Google Scholar